MEI Pharma (NASDAQ: LITS) is a clinical-stage pharmaceutical company developing drug candidates for oncology indications. Revenue has been generated through licensing and collaboration arrangements, including a commercialization agreement with Kyowa Kirin Co., Ltd. (KKC) under which MEI Pharma received an initial non-refundable payment of $100.0 million and is eligible for milestone payments plus royalties on net sales of zandelisib, its lead candidate, in certain territories. The company operates without approved commercial products as of the 10-K filed 2025-09-26, making it dependent on partnership economics and capital markets for funding. As of July 22, 2025, MEI Pharma entered into an asset management agreement with GSR Strategies LLC and an advisory agreement with Green Dragon Investments LLC, signaling a strategic shift. The company lists its securities on The Nasdaq Stock Market LLC and carries an accumulated deficit, with no retained earnings recorded on its consolidated balance sheet.

Revenue model

Licensing and collaboration revenue from the KKC Commercialization Agreement, including an initial $100.0 million non-refundable payment, potential regulatory and commercialization milestone payments, and royalties on net sales of zandelisib in Japan and other ex-U.S. territories. No product revenue from commercial sales is disclosed in the filing excerpts.

Products and services

Zandelisib, a pharmaceutical product candidate for human indications being developed and commercialized in collaboration with Kyowa Kirin Co., Ltd. under a license, development and commercialization agreement entered in April 2020.

Customers and end markets

Kyowa Kirin Co., Ltd. (KKC) is the primary commercial partner, holding co-exclusive U.S. rights and exclusive ex-U.S. rights to zandelisib. End market is oncology therapeutics. No other customers or end markets are identified in the filing excerpts.

Value-chain role

Drug developer and licensor. MEI Pharma discovers and develops drug candidates and out-licenses commercialization rights to partners such as KKC, retaining milestone and royalty economics.

Geographic exposure

United States and ex-U.S. territories under the KKC Commercialization Agreement, with Japan specifically named as a milestone and royalty-bearing market.

Source: SEC 10-K, filed 2025-09-26

Industry: Pharmaceutical Preparations Peers: AquaBounty Technologies Inc Unity Biotechnology, Inc. PharmaCyte Biotech Inc TYME TECHNOLOGIES, INC. Immunome Inc MERRIMACK PHARMACEUTICALS INC Sensei Biotherapeutics Inc Sera Prognostics Inc TScan Therapeutics Inc